Target concentration strategy for cyclosporin monitoring

Clinical Pharmacokinetics

Volumn 32, Issue 3, 1997, Pages 175-179

  Morris, Raymond G ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACCURACY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; HUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0030945989     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732030-00001     Document Type: Review

References (18)

1. Buchthal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol 1960; 2: 624-30
2. Kutt H, Winters W, Kokenge R, et al. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol 1964; 11: 642-8
3. Dusci LJ, Hackett P, Chiswell GM, et al. Comparison of cyclosporine in whole blood by high performance liquid chromatography, monoclonal fluorescent polarization immunoassay, and monoclonal enzyme-multiplied immunoassay. Ther Drug Monit 1992; 14: 327-32
4. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30: 107-40
5. Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1268-88
6. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36: 1510-6
7. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 1990; 36: 1841-6
8. Yatscoff RW. Report of the Bureau of Drug Research, Health Protection Branch and Canadian Society of Clinical Biochemists. Clin Biochem 1991; 24: 1-2
9. Morris RG. Australian cyclosporin therapeutic monitoring survey: 1993. Ther Drug Monit 1994; 16: 564-9
10. Holt DW, Johnston A, Roberts NB, et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994; 31: 420-46
11. Oellerich M, Armstrong IVW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642-54
12. Morris RG, Tett SE, Ray JE. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994; 16: 570-6
13. Jones TE, Morris RG. Survey of cyclosporin therapeutic ranges, assay methodology and use of 'sparing agents' in Australasian transplant centres. Ther Drug Monit. In press
14. Shiener LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles of therapeutics. New York: Macmillan, 1978: 71-109
15. Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287-91
16. Holford N, Black P, Couch R, et al. Theophylline target concentration in severe airways obstruction: 10 or 20mg/L? Clin Pharmacokinet 1993; 25: 495-505
17. 125I-RIA. Ther Drug Monit 1992; 14: 226-33
18. Johnston A, Holt DW. Concentration-controlled trials. What does the future hold? Clin Pharmacokinet 1995; 28: 93-9